CVRx (CVRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
The annual meeting is scheduled for June 1, 2026, to be held virtually, with voting on director elections and auditor ratification.
Only stockholders of record as of April 6, 2026, are eligible to vote; 26,430,915 shares are outstanding.
The company remains an emerging growth company until December 31, 2026, and utilizes related reporting exemptions.
Voting matters and shareholder proposals
Stockholders will vote to elect three Class II directors for terms expiring in 2029 and to ratify Grant Thornton LLP as the independent auditor for 2026.
The board recommends voting for all director nominees and for auditor ratification.
Stockholder proposals for the 2027 meeting must be received by December 21, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
The board will expand to eight members, with three Class II nominees: Michael Dale (new), Kevin Hykes, and Joseph Slattery.
Most directors are independent; Mr. Hykes is not. Mr. Ballinger will become independent board chair after the meeting.
The board is divided into three staggered classes, with annual elections for one class.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board holds regular executive sessions and reviews its leadership structure annually.
Latest events from CVRx
- Q1 2026 revenue rose 20% with strong U.S. growth, margin gains, and market expansion efforts.CVRX
Q1 202612 May 2026 - Votes are sought for three director nominees and auditor ratification at the 2026 annual meeting.CVRX
Proxy filing20 Apr 2026 - 2025 revenue up 10%, margins improve, and 2026 outlook projects continued growth.CVRX
Q4 202512 Feb 2026 - Q2 revenue up 24% to $11.8M; net loss widens, full-year outlook raised.CVRX
Q2 20242 Feb 2026 - Barostim delivers breakthrough heart failure therapy, targeting a $2.2B U.S. market with strong results.CVRX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Barostim targets a large unmet heart failure need with strong growth, evidence, and leadership focus.CVRX
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Q3 revenue up 27% to $13.4M; Barostim adoption, reimbursement gains, and strong cash position.CVRX
Q3 202418 Jan 2026 - Market expansion, clinical evidence, and reimbursement improvements drive growth and adoption.CVRX
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Reimbursement wins, commercial focus, and strong cash position drive growth outlook.CVRX
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026